Stocks directory

2157.HK

LEPU BIO-B

HKEXHealthcareBiotechnology

HK$4.18

-1.88%

2026-06-01

About LEPU BIO-B

Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drug candidates in anti-tumor targeted therapy and oncology immunotherapy in China and internationally. The company offers PUYOUHENG (Pucotenlimab Injection), a humanized IgG4 mAb against human PD-1 for the treatment of MSI-H/dMMR solid tumors solid tumors and melanoma. It is also developing MRG003 that is in phase III clinical study for treating nasopharyngeal cancer, and head and neck squamous cell carcinoma; CMG901 CLDN18.2-targeted ADC, which is in phase III trials for treating gastric and gastroesophageal junction carcinoma and other solid tumors; and MRG004A TF-targeted ADC, which is in phase III clinical trial for treating pancreatic ductal adenocarcinoma. In addition, the company is developing CG00705 Oncolytic virus for treating bacillus calmette-guerin unresponsive non-muscle invasive bladder cancer; and MRG002, which is in phase III trials to treat breast cancer, as well as HER2-positive. Further, the company is developing MRG001 CD20-targeted ADC for treating non-Hodgkin's lymphoma; MRG006A, MRG007, and CTM012 for the treatment of solid tumors. Lepu Biopharma Co., Ltd. was incorporated in 2018 and is headquartered in Shanghai, China. Lepu Biopharma Co., Ltd. operates as a subsidiary of Ningbo Houde Yimin Information Technology Co., Ltd.

Key Fundamentals

P/E Ratio

25.06

EPS (TTM)

HK$0.17

ROE

25.3%

Revenue Growth (YoY)

100.0%

Profit Margin

28.0%

Debt/Equity

78.06

Price/Book

4.79

Beta

-0.41

Market Cap

HK$7.69B

Avg Volume (10D)

9.1M

Recent Breakout Signals

No recent breakout signals detected for 2157.HK.

Recent Price Range (60 Days)

60D High

HK$6.65

60D Low

HK$3.90

Avg Volume

13.2M

Latest Close

HK$4.18

Get breakout alerts for 2157.HK

Sign up for Breakout Scanner to receive daily notifications when 2157.HK triggers breakout signals. Build custom AI screeners and backtest strategies.

Start Free Trial

7-day free trial.

LEPU BIO-B (2157.HK) is listed on the Hong Kong Exchanges (HKEX). Breakout Scanner monitors 2157.HK daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. 2157.HK operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.